<DOC>
	<DOCNO>NCT00669669</DOCNO>
	<brief_summary>This phase I/II trial study side effect best dose temozolomide give together radiation therapy , carmustine , O6-benzylguanine , patient ' stem cell ( autologous ) transplant treat patient newly diagnose glioblastoma multiforme gliosarcoma . Giving chemotherapy , temozolomide , carmustine , O6-benzylguanine , radiation therapy peripheral stem cell transplant stop growth cancer cell stop divide kill . Giving colony-stimulating factor , filgrastim plerixafor , certain chemotherapy drug , help stem cell move bone marrow blood collect store . Chemotherapy radiation therapy give prepare bone marrow stem cell transplant . The stem cell return patient replace blood-forming cell destroy chemotherapy radiation therapy .</brief_summary>
	<brief_title>O6-Benzylguanine-Mediated Tumor Sensitization With Chemoprotected Autologous Stem Cell Treating Patients With Malignant Gliomas</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Determine safety feasibility infuse autologous granulocyte colony-stimulating factor ( G-CSF ) ( filgrastim ) mobilize stem cell transduce Phoenix-gibbon ape leukemia virus ( GALV ) -pseudotype vector express methylguanine methyltransferase ( MGMT ) ( P140K ) . II . Define dose BCNU ( carmustine ) result efficient engraftment gene modify cell give peripheral blood stem cell support . SECONDARY OBJECTIVES : I . Determine engraftment gene-modified cell condition BCNU . II . Determine ability select gene-modified cell vivo regimen . III . Evaluate molecular clonal composition gene-modified cell chemotherapy temozolomide . IV . Observe patient clinical anti-tumor response . V. Determine correlation level MGMT ( P140K ) mark toxicity , temozolomide dose achieve , response . VI . Characterize toxicity associate regimen . OUTLINE : This phase I , dose-escalation study temozolomide follow phase II study . PART I : Within 35 day surgery , patient undergo 3 dimensional ( 3D ) conformal intensity-modulated radiation therapy ( IMRT ) proton beam radiation therapy daily 5 day per week 6 week . Patients receive filgrastim subcutaneously ( SC ) day -7 -3 begin stem cell collection 4th day filgrastim administration ( 3 apheresis ) . Patients may also receive plerixafor SC day -5 -3 . The CD34+ stem cell separate patient 's stem cell transduce Phoenix-RD114 pseudotype vector ( retrovirus ) . One day apheresis complete , patient receive carmustine intravenously ( IV ) 3 hour follow 2 hour later temozolomide orally ( PO ) . At least twenty-four hour completion carmustine temozolomide , patient undergo reinfusion genetically-modified stem cell . PART II : Beginning approximately 4 week completion Phase 1 study , patient receive O6-benzylguanine IV continuously 48 hour follow temozolomide PO within 1 hour . Treatment may repeat least every 28 day total 24 course absence disease progression unacceptable toxicity . After completion study treatment , patient follow every 1-3 month 2 year , every 3-6 month 3 year , annually thereafter 10 year .</detailed_description>
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Glioma</mesh_term>
	<mesh_term>Gliosarcoma</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Carmustine</mesh_term>
	<mesh_term>O ( 6 ) -benzylguanine</mesh_term>
	<mesh_term>JM 3100</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>Patients glioblastoma multiforme gliosarcoma The patient legal guardian must able comprehend inform consent form sign prior patient enrollment Karnofsky performance status time study entry must &gt; = 70 % Life expectancy &gt; = 3 month Patients must agree undergo repeat clinical neurological examination brain magnetic resonance imaging ( MRI ) appropriate contrast every cycle chemotherapy White blood cell ( WBC ) &gt; 3000/ul Absolute neutrophil count ( ANC ) &gt; 1500/ul Platelets &gt; 100,000/ul Hemoglobin &gt; 10 gm/100ml Total direct bilirubin &lt; 1.5 time upper limit laboratory normal Serum glutamic oxaloacetic transaminase ( SGOT ) serum glutamate pyruvate transaminase ( SGPT ) = &lt; 3 time upper limit laboratory normal Alkaline phosphatase = &lt; 3 time upper limit laboratory normal Blood urea nitrogen ( BUN ) &lt; 1.5 time upper limit laboratory normal Serum creatinine &lt; 1.5 time upper limit laboratory normal Left ventricular ejection fraction ( LVEF ) &gt; = 40 % , however , subject LVEF range 4049 % cardiology clearance prior intervention MGMT promoter methylation analysis surgically resect tumor tumor biopsy must demonstrate unmethylated hypomethylated MGMT promoter status Patients cardiac insufficiency LVEF &lt; 40 % ; history coronary artery disease arrhythmia , require require ongoing treatment Patients active pulmonary infection and/or pulse oximetry &lt; 90 % correct diffusion capacity lung carbon monoxide ( DLCO ) &lt; 70 % predict Active systemic infection Patients human immunodeficiency virus ( HIV ) positive Pregnant lactate woman ; betahuman chorionic gonadotropin ( HCG ) level obtain woman childbearing potential ; fertile men woman use effective contraception Previous chemotherapy malignancy include temozolomide , dacarbazine ( DTIC ) prior nitrosourea Diabetes mellitus Bleeding disorder Methylated hypermethylated MGMT promoter status within tumor tissue Medical psychiatric condition opinion protocol chairman would compromise patient 's ability tolerate protocol Prior interstitial radiotherapy , stereotactic gamma knife surgery implant BCNUwafers</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>